Official Website: Rebel Medicine
source confidence: Medium status: Useful updated 2026-06-19
Summary
Rebel Medicine's official website describes the company as developing disruptive, non-opioid solutions for acute pain, with a lead asset Alevatrix™ positioned as a best-in-class long-acting local anesthetic for non-opioid postoperative pain management.
Useful Claims
- The company states it is focused on developing disruptive, non-opioid solutions for acute pain.
- Rebel Medicine markets Alevatrix™ as a long-acting local anesthetic for non-opioid postoperative pain management.
- The site reports completion of a Pre-IND meeting for Alevatrix™ (September 30, 2024).
- The site reports publication of data from Alevatrix™ large-animal preclinical studies (August 6, 2024).
- The site reports NSF SBIR Phase 2b and NIH SBIR Phase 1 grant awards (October 11, 2023).
- Rebel Medicine is headquartered in Salt Lake City, Utah (per company press materials linked from the site).
Verbatim
"Rebel is focused on developing disruptive, non-opioid solutions for acute pain." — Home page, heading
"We're developing the best-in-class long-acting local anesthetic for non-opioid postoperative pain management." — Home page, pipeline summary
"Rebel Medicine completes Pre-IND meeting for lead asset Alevatrix™" — Home page, "Latest news" (30 September 2024)
Reliability Notes
This is an official company source. Clinical-stage claims, regulatory milestones, and competitive positioning ("best-in-class") are company assertions and should be confirmed against FDA filings, peer-reviewed publications, and independent clinical data before being treated as high-confidence evidence. The site does not disclose detailed formulation science, trial timelines, or financing on the homepage.